Table 1.
Clinicopathological features of the studied tumors
| Tumor | Tumor features & outcome | Tumor response to the GSK2126458 treatment | ||||
|---|---|---|---|---|---|---|
| Morphology | Caspase-3 activity | Immunohistochemistry | ||||
| Caspase-3 | Cytochrome C | Annexin A2 | ||||
| I | - Invasive ductal carcinoma, NOS; grade 3; CS IIB; size 4.5 cm | + | + (↑15.7 fold) | + (10% → 20%) | ¶ (2+ → 2+) | ¶ (3+ → 2+) |
| - ER+, PR-, Her2-neu+, Ki-67 = 70% | ||||||
| - k c = 0.17 μM O2 min-1 mg-1 | ||||||
| - Age 73 yr; alive at 2 yr with lung and lymph nodes metastases | ||||||
| II | - Invasive ductal carcinoma, NOS, NH grade 2; CS IIB; size 4.5 cm | - | + (↑3.6 fold) | + (1% → 3%) | + (2+ → 3+) | ¶ (2+ → 2+) |
| - ER+, PR+, Her2-neu-, Ki-67 = 5% | ||||||
| - k c = 0.15 μM O2 min-1 mg-1 | ||||||
| - Age 58 yr; free of disease at 18 months | ||||||
| III | - Invasive lobular carcinoma, NOS; NH grade 3; and lobular carcinoma in situ (60% of the tumor mass; the studied component); CS IIIA; size 6.0 cm | + | - | - (1% → 1%) | ¶ (3+ → 3+) | ± (!) (2+ → 3+) |
| - ER+, PR+, Her2-neu-, Ki-67 = 30% | ||||||
| - k c = 0.22 μM O2 min-1 mg-1 | ||||||
| - Age 62 yr; free of disease at 18 months | ||||||
| IV | - Invasive ductal carcinoma, NOS; NH grade 2; CS IIB; size 2.3 cm | + | - | + (1% → 2%) | + (2+ → 3+) | + (2+ → 3+) |
| - ER+, PR+, Her2-neu-, Ki-67 = 20% | ||||||
| - k c = 0.06 μM O2 min-1 mg-1 | ||||||
| - Age 41 yr; free of disease at 18 month | ||||||
| V | - Ovarian dysgerminoma; CS 1A; size 5.0 cm | + | nd | - | ǂ (3+ → ?) | ǂ (2+ → ?) |
| - k c = nd | ||||||
| - Age 22 yr; free of disease at 18 months | ||||||
| VI | - Ovarian serous carcinoma; CS IIIB | - | - | - (1% → 1%) | ¶ (3+ → 3+) | ¶ (2+ → 2+) |
| - k c = nd | ||||||
| - Age 49 yr; free of disease at 12 months | ||||||
| VII | - Moderately differentiated adenocarcinoma, colorectal origin; CS IV | - | - | - (5% → 0%) | - (1+ → 1+) (↑Necrosis) | ¶ (2+ → 2+) |
| - k c = nd | ||||||
| - Age 60 yr; lost to follow-up | ||||||
| VIII | - Poorly differentiated signet ring adenocarcinoma of gastric origin, metastatic to the ovary; CS IV | - | + | + (2% → 4%) | ¶ (3+ → 3+) | + (2+ → 3+) |
| - k c = nd | ||||||
| - Age 66 yr; advanced disease on palliative care | ||||||
NOS, Not otherwise specified; ER, Estrogen receptor; PR, Progesterone receptor; k c, rate of cellular respiration; CS, clinical stage; NH grade, Nottingham histological grade; nd, not done due to insufficient tumor sample; ¶, highly positive staining in treated and untreated specimens; !, inconsistent result (Additional file 2); ǂ, highly positive staining in untreated specimen (treated specimen was lost). Values in parentheses reflect treatment-associated changes in the expression intensity.